| VRTX |
Report |
JOURNAVX Revenue (Q2 2026) |
BEAT |
pred ~$55M vs. cons $49.1M |
MEDIUM |
| VRTX |
Report |
ALYFTREK Revenue (Q2 2026) |
MISS |
pred ~$510M vs. cons $521M |
MEDIUM |
| VRTX |
Report |
Total Revenue (Q2 2026) |
IN-LINE |
pred ~$3.22B vs. cons $3.221B |
MEDIUM |
| VRTX |
Guide |
FY 2026 Revenue (Crinetics raise) |
BETTER |
guide ~$13.175B midpoint vs. cons $13.053B |
MEDIUM |
| VRTX |
Guide |
FY 2026 Non-GAAP EPS (Crinetics opex dilution) |
LOWER |
guide ~$17.90 midpoint vs. cons $18.23 |
MEDIUM |
| VRTX |
Guide |
JOURNAVX FY 2026 Revenue (qualitative) |
BETTER |
guide ~$250M vs. cons $239.8M |
MEDIUM |
| VRTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| VRTX |
Return |
5-day cumulative residual |
-4.0% (FADE) |
FADE — sell-side EPS cuts from Crinetics opex raise weigh on the stock over the following days; JOURNAVX beat provides partial offset but does not reverse the EPS dilution narrative |
MEDIUM |